Sonuç olarak çalışmamızda hipertiroidisi olan gebe hastaların çoğunluğu gestasyonel tirotoksikoz hastası iken, hipotiroidisi olan hastaların çoğunluğu ise subklinik hipotiroidi hastası idi. Hipertiroidisi olan gebe hastaların %1'inde Graves saptandı. Anti-TPO pozitifliği hipertiroidisi olan hastaların sadece 1'inde (%8.3) saptanmışken, hipotiroidisi olan hastaların 15 'inde (%93.7) izlendi. Hipotiroidisi olan hastaların çoğunluğu subklinik hipotiroidi iken, diğer hastalar klinik hipotiroidi hastası idi. Olgularımızın 7'sinde (%15.6) prematür gebelik görüldü ve otoimmunite ile prematüre gebelik arasında anlamlı fark izlenmedi. Nodül olgularımızın %24'ünde izlendi ve TSH yüksekliği, yaş ile nodül sıklığı arasında anlamlı fark bulunamadı. Sadece 1 hastaya ince iğne aspirasyon biyopsisi yapıldı ve sonucu önemi belirsiz atipi olarak raporlandı.
Ancak çalışmamızda gebe hastalarda beslenme durumu, iyot kullanım durumu ve idrarda iyot bakılmaması gibi sınırlılıklarının yanısıra, hasta sayısının az olması da çalışmamızın genellenebilirliğini sınırlamaktadır. Bu yüzden çalışmanın daha geniş hasta grupunda yapılmasının daha uygun olabileceğini düşünmekteyiz.
Türkiyenin iyod eksikliği bölgesi olması, tiroid hormon eksikliğinin gebelikte bir çok olumsuz sonuçlara yol açma riskinin olması ve TSH ölçümlerinin ülkemizde kabul edilebilir bir maaliyette olması nedeni ile gebe kalmayı planlayan tüm kadınlarda ve tüm gebelerde başlangıçta TSH ölçümü yapılmalıdır. Türkiye Endokrinoloji ve Metabolizma Derneğinin önerisi de bu yöndedir. Gebelerde rutin tiroid fonksiyon testlerine bakılarak erken tanı konmalı ve tedavisi başlanarak gebelik komplikasyonları önlenmeli, şüpheli nodüllere gebelik döneminde ince aspirasyon biopsisi yapılarak malignite ekarte edilmelidir.
Bizim çalışmamızda gebelerde tiroid hastalıkları ile nodül sıklığı, otoimmunite ve prematüre doğum arasında ilişki değerlendirilmiş olup, istatiksel anlamlı sonuç bulunamamıştır. Ancak hasta sayısının kısıtlı olması nedeniyle daha geniş kapsamlı çalışma serilerine ihtiyaç olduğu görülmüştür.
KAYNAKLAR
1. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C et al 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017; Volume 27, Number 3: 315-389. DOI: 10.1089/thy.2016.0457.
2. Tiroid Hastalıkları Tanı ve Tedavi Kılavuzu 2017. Türkiye Endokrinoloji ve Metabolizma Derneği. Türkiye Klinikleri Yayın Seri No: 157. 2017. ISBN: 978- 975-9118-66-2.
3. Casey BM, Leveno KJ.: Thyroid Disease in Pregnancy. Obstet Gynecol. 2006;108(5):1283- 1292.
4. Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M, Kinthaert J, Robijn C, Grun JP, de Nayer P1991.Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab73:421–427.
5. Struve CW, Haupt S, Ohlen S1993.Influence of frequency of previous pregnancies on the prevalence of thyroid nodules in women without clinical evidence of thyroid disease.Thyroid3:7– 9
6. Kung AW, Chau MT, Lao TT, Tam SC, Low LC2002.The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab87:1010–1014.
7. Gardner, David G.,and Dolores M. Shoback. Greenspan's Basic and Clinical Endocrinology. Mc GrawHill Professional, 2011.
8. Adult human thyroid weight. Pankow BG, Michalak J, McGee MK.Health Phys. 1985;49(6):1097.
9. Thyroid size determined by ultrasound. Influence of physiological factors and non-thyroidal disease. Hegedüs L Dan MedBull. 1990;37(3):249.
10. Costanzo M, Caruso LA, Veroux M,et al. Thelobe of Zuckerkandl: an important sign of recurrent laryngeal nerve. AnnItalChir 2005;76(4):33740.
11. Miller FR. SurgicalAnatomy of theThyroid and Parathyroid Glands. OtolaryngolClin North Am 2003;44:1443-1458.
12. Kaplan EL. Thyroid and Parathyroid. In: Sabiston DC Jr, Lyerly HK, eds. Principles of surgery. New York: McGraw-Hill, Offers a Basic Review of Thyroid Anatomy 1994.
13. Pilar Santisteban. 2005. Development and anatomy of the hypothalamic-pituitary-throidaxis. Lewis E.Braverman &Robert D. Utiger. The Thyroid. Lippincott 9.ed. 2005; S:7.
14. Braun EM, Windisch G, Wolf G, et al. The pyramidal lobe: clinical anatomy and its importance in thyroid surgery. Surg Radiol Anat 2007; 29:21.
15. Allard RH. The thyroglossal cyst. Head Neck Surg 1982; 5:134.
16. WHO Secretariat, Andersson M, de Benoist B, et al. Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. PublicHealthNutr 2007; 10:1606.
17. Zimmermann MB. Iodine deficiency. EndocrRev 2009; 30:376.
18. Spitzweg C, Heufelder AE, Morris JC. Thyroidiodine transport. Thyroid 2000; 10:321.
19. Arvan P, DiJeso B. Thyroglobulin structure, function, and biosynthesis. In: TheThyroid: Fundamental and ClinicalText, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.77.
20. Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion. (First of twoparts). N Engl J Med 1979; 301:239.
21. Bianco AC1, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006 Oct;116(10):2571-9.
22. Duntas LH. Selenium and the thyroid: a close-knit connection. J ClinEndocrinolMetab 2010; 95:5180.
23. Engler D, Burger AG. The deiodination of the iodothyronines and of their derivatives in man.Endocr Rev 1984; 5:151.
Temel ve Klinik Metin, 9.,Braverman LE, Utiger RD (Eds), Lippincott Williams ve Wilkins, Philadelphia 2005. s.97.
25. Bartalena L. Tiroid hormonu bağlayıcı proteinlerle ilgili çalışmalarda son başarılar. EndocrRev 1990; 11:47.
26. Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. EndocrRev2001; 22:451..
27. Larsen PR, Silva JE, Kaplan MM. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. EndocrRev 1981; 2:87.
28. Magner JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 1990; 11:354
29. Jackson IM. Thyrotropin-releasing hormone. N Engl J Med 1982; 306:145.
30.Williams TC, Kelijman M, Crelin WC, et al. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 1988; 66:39.
31. Beers MH, Berkow R. Thyroid Disease. İn The Merck Manual Of Diagnosis and Therapy. Seventeenth Edition .İstanbul: Nobel Yayıncılık; 1999;17:81-99.
32. Sadler GP, Clark OH, Schwartz SI, Shires G, Spencer FC(ed). Thyroid and parathyroid. in Principles of Surgery. 7th ed. New York: McGraw-Hill; 1999; 1661-1687.
33. İşgör A. Tiroid fizyolojisi. İşgör A (ed). Tiroid Hastalıkları ve Cerrahisi. 1. baskı. İstanbul Avrupa Tıp Kitapçılık 2000;1:69-122.
34. Speroff L, Fritz MA. Tiroid Hastalıkları. Editörler Özkan S. Klinik Jinekolojik Endokrinoloji ve İnfertilite 7. Baskı İstanbul: Güneş Kitabevi; 2007;7:806-823..
35. Kotani T, Rinsho Byori. Department of Laboratory Medicine, Myazaki Medical Collage. Anti-TPO autoantibodies Apr 1998; 46: 324-30
36. Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991; 151:165.
37. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.
38. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.
39. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004; 89:6077.
40. Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.
41. Trzepacz PT, Klein I, Roberts M, et al. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87:558.
42. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.
43. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95:2715.
44. Thomas FB, Mazzaferri EL, Skillman TG. Apathetic thyrotoxicosis: A distinctive clinical and laboratory entity. Ann Intern Med 1970; 72:679.
45. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
46. Bemben DA, Hamm RM, Morgan L, et al. Thyroid disease in the elderly. Part 2. Predictability of subclinical hypothyroidism. J Fam Pract 1994; 38:583.
47. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.
48. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34:77. 49. Szabolcs I, Podoba J, Feldkamp J, et al. Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis and abundant iodine intake. Clin Endocrinol (Oxf) 1997; 47:87.
50. Mc Elduff A, Morris J 2008.Thyroid function tests and thyroid autoantibodies in an unselected population of women undergoing first trimester screening for aneuploidy. Aust N Z J Obstet Gynaecol 48:478–480.
51. Mullis-Jansson SL, Argenziano M, Corwin S, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117:1128.
52. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.
53. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005; 90:124. 54. Roos A, Linn-Rasker SP, van Domburg RT, et al. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med 2005; 165:1714.
55. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2007;92(8):1–47. doi: 10.1210/jc.2007-0141.
56. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. EndocrRev 1997; 18:404.
57. Negro R, Farmoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab. 2006;91:2587–2591. doi: 10.1210/jc.2005-1603.
58. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J ClinEndocrinolMetab 1987; 65:689.
59. Ballabio M, Poshychinda M, Ekins RP. Pregnancy-induced changes in thyroid function: role of human chorionic gonadotropin as putative regulator of maternal thyroid. J Clin Endocrinol Metab 1991; 73:824.
60. Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125Iin corporation and denovo synthesized thyroid hormone release in human thyroid follicles. J ClinEndocrinolMetab 1995; 80:473.
61. Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J ClinEndocrinolMetab 1990; 71:276.
62. Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.
63. Haddow JE, Knight GJ, Palomaki GE, Mc Clain MR, Pulkkinen AJ 2004 The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. J MedScreen11:170–174.
64. Panesar NS, Li CY, Rogers MS 2001 Reference intervals for thyroid hormones in pregnant Chinese women. Ann Clin Biochem38:329–332.
65. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W, American Thyroid Association Task force on Thyroid Disease During Pregnancy and Postpartum 2011 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21:1081–1125.
66. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S 2012 Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practic eguideline. J Clin Endocrinol Metab 97:2543–2565.
67. Leung AM, Pearce EN, Braverman LE. Iodinecontent of prenatal multivitamins in the United States. N Engl J Med 2009; 360:939.
68. Williams TC, Kelijman M, Crelin WC, et al. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 1988; 66:39.
69. Vulsma T, Gons MH, de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989; 321:13.
70. Bajoria R, Fisk NM. Permeability of human placenta and fetal membranes to thyrotropin- stimulating hormone in vitro. Pediatr Res 1998; 43:621.
71. Sangita Nangia Ajmani, Deepa Aggarwal, Pushpa Bhatia, Manisha Sharma, Vinita Sarabhai, and Mohini Paul JObstet Gynaecol India 2014 Apr; 64(2): 105–110Prevalence of Overt and Subclinical Thyroid Dysfunction Among Pregnant Women and Its Effect on Maternal and Fetal Outcome10.1007/s13224-013-0487-y.
72. American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol 2002; 100:387.
73. Bussen S, Steck T. Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Hum Reprod 1995; 10:2938.
74. He X, Wang P, Wang Z, et al. Thyroidantibodiesand risk of preterm delivery: a meta-analysis of prospective cohort studies. Eur J Endocrinol 2012; 167:455.
75. Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis. ClinEndocrinol (Oxf) 2011; 74:513.
76. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011; 342:d2616.
77. Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM, Hofman A, Ross HA, Hooijkaas H, Tiemeier H, Bongers-Schokking JJ, Jaddoe VW, Visser TJ, Steegers EA, Medici M, Peeters RP2013Hypothyroxinemia and TPO-
antibody positivity are risk factors for premature delivery: the generation R study. J Clin Endocrinol Metab98:4382–4390.
78. Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. N Engl J Med 2019; 380:1316
79. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331:1072
80. Rasmussen NG, Hornnes PJ, Hegedüs L. Ultrasonographically determined thyroid size in pregnancy and postpartum: the goitrogeni ceffect of pregnancy. Am J ObstetGynecol 1989; 160:1216.
81. Rotondi M, Amato G, Biondi B, et al. Parity as a thyroid size-determining factor in areas with moderate iodine deficiency. J ClinEndocrinolMetab 2000; 85:4534.
82. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: TheAmerican Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated ThyroidCancer. Thyroid 2016; 26:1.
83. Karger S, Schötz S, Stumvoll M, et al. Impact of pregnancy on prevalence of goitre and nodular thyroid disease in women living in a region of borderline sufficient iodine supply. HormMetabRes 2010; 42:137.
84. Tan GH, Gharib H, Goellner JR, et al. Management of thyroid nodules in pregnancy. ArchInternMed 1996; 156:2317.- mith LH.
85. Danielsen B,AllenME,Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancerregistry. Am J ObstetGynecol 2003; 189:1128.
86. Burch HB, Burman KD, Cooper DS, et al. A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules. J ClinEndocrinol Metab 2016; 101:2853
87. Kabalak T, Tiroid El Kitabı. Tiroid bezi anatomisi ve embriyolojisi, Ege Üniversitesi Basımevi 2012; 1: S: 1-17, S:475-483.
88. Fitzpatrick DL, Russell MA.: Diagnosis and Management of Thyroid Disease in Pregnancy. Obstet Gynecol Clin N Am. 2010;37:173-193.
89. Susan J Mandel G.Burrow,2000 De Groot Endokrinology 2446.
90. Hersman JM .1999.Human chorinonic gonadotropin and the thyroid :Hyperemesis gravidarum and the trophoblastic tumors .Thyroid .9(7):653-7.
91. Cooper DS, Laurberg P 2013 Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol1:238–249.
92. Wen and ark. A clinical study on gestational transient thyrotoxicosis. 2008 Dec;47(12):1003- 7.
93. Masiukiewicz US, Burrow GN .1999.Hyperthrodisim in pregnancy .Diagnosis and treatment .Thyroid .9(7):647-52 .
94. Mestman JH.1998. Hyperthyroidism in pregnancy .Endocrinol and Metab Clin North Am.27(1):127-49.
95. Bahn RS ve ark.2011.Hyperthyroidism and other causes of thyrotxicosis :management guidlines of the American Thyroid Association and American Association of Clinical Endocrinologists.Endocr Pract .17(3):456-520 .
96. Tagami T ve ark .2007 The incidence of Gestasyonal Hyperthyroidism and Postpartum Thyroiditis in Treated Patients with Graves ' disease .Thyroid 17(8) :767-72.
97. Birte Nygaard ve ark. Hyperthyroidism in pregnancy. 2015; 2015: 0611.
98. Krassas ve ark . Thyroid diseases during pregnancy: A number of importantissues. 2015 Jan- Mar;14(1):59-69.
99. Gärtner R. Dtsch Med Wochenschr. Thyroid disease in pregnancy .2009 Jan;134(3):83-6. doi: 10.1055/s-0028-1105894. Epub 2009 Jan 13. Review. German.
100. Karabinas ve ark.Thyroid diseases in pregnancy.1998 Nov;18(6):509-15
101. Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH 2010.Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. Thyroid20:989–993.
102. Shields BM ve ark.2013.Five years follow -up for women with subclinical hypothyroidism in pregnancy .J Clin Endocrinol Metab .98(12):E1941-5.
103. Schneuer FJ .Ve ark.2012.Association and predictive accuracy of high TSH serum levels in first trimester and adverse pregnancy outcomes .J Clin Endocrinol Metab .97(9) :3115-22.
104. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF2007.Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol 109:1129–1135.
105. Lopez Munoz ve ark. Prevalence of hypothyroidism during pregnancy in a highly specialised referral centre in Mexico. 2016 Nov;36(8):1069-1075.
106. Dhanwal DK ve ark.Prevalence of hypothyroidism in pregnancy: An epidemiological study from 11 cities in 9 states of India. 2016 May-Jun;20(3):387-90.
107. S Arora ve ark. Effectiveness of a counselling intervention implemented in antenatal setting for pregnant women facing domestic violence: a pre-experimental study. https://doi.org/10.1111/1471- 0528.15846.
108. Blumental NJ ve ark. Prevalence of thyroid dysfunction and thyroid antibodies in a private obstetrical practice in Sydney. 2016 Jun;56(3):307-11.
109. Maraka S, Ospina NMS, O'Keeffe DT, et al. Subclinical hypothyroidism in pregnancy: A systematic review and meta-analysis. Thyroid. 2016;26:580–590.
110. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. Eur J Endocrinol. 2016;174:51–57.
111. Balucan ve ark. Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. 2013;2013:182472.
112. Moreno Reyes ve ark. High prevalence of thyroid disorders in pregnant women in a mildly iodine- deficient country: a population-based study. 2013 Sep;98(9):3694-701.
113. Carla Lorena Macchia de Sánche ve ark. Prevalence of thyroid autoimmunity in a population of pregnant women in Santa Marta, Magdalena (Colombia) http://dx.doi.org/10.18597/rcog.3161 .
114. Karakosta P, Alegakis D, Georgiou V, et al. Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J Clin Endocrinol Metab 2012;97:4464–72.
115. Stagnaro-Green A. Maternal thyroid disease and preterm delivery. J Clin Endocrinol Metab 2009;94:21–5.
116. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG2005.Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 105:239–245. 117. Su PY, Huang K, Hao JH et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: A prospective population‐based cohort study in China. J Clin Endocrinol Metab2011; 96: 3234–3241.
118. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011; 342:d2616.
119. Saki ve ark.T hyroid autoimmunity in pregnancy and its influences on maternal and fetal outcome in Iran (a prospective study) https://doi.org/10.3109/07435800.2014.966384.
120. Sullivan Scott ve ark. Thyroid nodul and thyroid cancer in pregnancy .June 2019 . 62(2):365–372.